Omnicell logo

Omnicell(NASDAQ) OMCL

Market Cap$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+272%
5 Year-78%
1 Year+20%
1 Month+11%
Premium Feature
Moneyball Superscore
60/100
$35.76
+1.05%
+0.37Today
After hours$35.80+$0.04 (+0.10%)
Omnicell last closing stock price
MetricPriceDate
Last closeUSD 35.812026-10-19
Omnicell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.87%USD 36.872026-10-12
1 month+11.11%USD 32.232026-09-18
3 month-14.39%USD 41.832026-07-21
Year to date-20.95%USD 45.302025-12-31
1 year+19.77%USD 29.902025-10-17
3 year-9.64%USD 39.632023-10-20
5 year-78.3%USD 165.012021-10-20
Since inception+272.13%USD 9.512001-08-07

Omnicell Financials at a Glance

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.25B

Net Income (TTM)

$39.08M

EPS (TTM)

$0.85

P/E Ratio

42.34

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$35.76

Volume

426,255.519

Open

$35.39

Previous Close

$35.81

Daily Range

$35.12 - $36.20

52-Week Range

$29.09 - $55.00

Estimated Earnings Date

Oct 29, 2026

OMCL: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Omnicell

**Omnicell, Inc.** NASDAQ:OMCL makes machines that sort and give out medicine.

These tools help nurses and pharmacists find drugs quickly.

The technology makes hospital work safer and reduces mistakes.

Automated Health and Safety

  • Point of Care: Automated dispensing systems like Titan XT that store medications; represented 56% of total revenues in the six-month period ended June 30, 2026.
  • Service Solutions: Technical support and software as a service, which is software delivered over the internet; accounted for 44% of total revenues in the six-month period ended June 30, 2026.
  • Central Pharmacy: Robotic platforms and carousels used to manage inventory and mix ingredients to create sterile medications given through a vein.
  • Outpatient Services: Tools for specialty pharmacies and a patient engagement platform that help retail pharmacies manage complex drug programs.

Expanding the Digital Pharmacy

  • Introduced XTExtend to provide a console upgrade for existing automated medication cabinets.
  • Expanded specialty pharmacy services to help hospitals manage complex and expensive medication programs.
  • Implemented nearshoring of manufacturing to Mexico to reduce the impact of global trade tariffs.
  • Launched the OmniSphere cloud-based platform to provide data insights across multiple healthcare settings.

Why Efficiency Matters

The company focuses on its vision of the Autonomous Pharmacy, a framework designed to reach zero-error medication management. Most business operations are concentrated in the United States, which accounted for 90% of total revenues in the first half of 2026.

Checking the Pulse

  • Total revenues reached $622.1 million for the six months ended June 30, 2026, up 11% year over year.
  • Gross profit was $293.3 million for the six months ended June 30, 2026, up 23% year over year.
  • Net income for the six-month period ended June 30, 2026, was $35.6 million.
  • Cash and cash equivalents totaled $292.2 million as of June 30, 2026.

The Evolving Pharmacy

Omnicell has transitioned from selling individual pieces of equipment to offering a unified platform for medication management. Its move toward subscription-based services and cloud intelligence helps healthcare providers manage rising costs and labor shortages.

AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Employees

3,580

CEO

Randall A. Lipps

Headquarters

Fort Worth, TX 76137, US

OMCL Financials

Key Financial Metrics (TTM)

Gross Margin

44.77%

Operating Margin

4.73%

Net Income Margin

3.13%

Return on Equity

3.13%

Return on Capital

0.81%

Return on Assets

1.96%

Earnings Yield

2.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.61M

Volume

426.26K

Avg. Volume

655.38K

Financials (TTM)

Gross Profit

$558.13M

Operating Income

$58.96M

EBITDA

$147.31M

Operating Cash Flow

$182.67M

Capital Expenditure

-$41.27M

Free Cash Flow

$141.40M

Cash & ST Invst.

$307.01M

Total Debt

$200.00M

Omnicell Performance Analysis

Omnicell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,295,947,00014.5%
20232023-12-31USD 1,147,112,000-11.5%
20242024-12-31USD 1,112,238,000-3.0%
20252025-12-31USD 1,184,845,0006.5%
Omnicell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.9%
Q42025-12-311.1%
Q12026-03-31-1.3%
Q22026-06-300.8%
Omnicell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.12-92.4%
20232023-12-31USD -0.45N/A
20242024-12-31USD 0.27N/A
20252025-12-31USD 0.04-83.6%
Omnicell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-137.6%
Q12026-03-31654.3%
Q22026-06-30108.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$312.21M

+7.4%

Gross Profit

$152.94M

+19.8%

Gross Margin

48.98%

N/A

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$468.71K

N/A

Employees

3,485

N/A

Net Income

$24.29M

+330.7%

EBITDA

$53.14M

+63.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$307.01M

-25.4%

Total Debt

$200.00M

-48.0%

Accounts Receivable

$227.05M

-2.4%

Inventory

$96.72M

-8.6%

Long Term Debt

$188.51M

-4.7%

Short Term Debt

$11.49M

-93.8%

Return on Assets

1.96%

N/A

Return on Invested Capital

3.80%

N/A

Free Cash Flow

$60.61M

+95.7%

Operating Cash Flow

$69.55M

+62.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,704.21+0.01%
^DJIDJI
$52,064.30+0.00%
^IXICNASDAQ
$26,465.53+0.01%
BTCBitcoin
$81,947.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$98.65+5.32%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.63-5.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.52-3.55%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.64+3.56%

Questions About OMCL

What is the current price of Omnicell?

Omnicell is trading at $35.81 per share.

What is the 52-week range for Omnicell?

Over the past 52 weeks, Omnicell has traded between $29.09 and $55.00.

How much debt does Omnicell have?

As of the most recent reporting period, Omnicell reported total debt of $200.00M.

How much cash does Omnicell have on hand?

Omnicell reported $322.75M in cash and cash equivalents in its most recent financial results.

What is Omnicell’s dividend yield?

Omnicell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.